1. Inicio
  2. Publicaciones
  3. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort

eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Teira, R
  • Diaz-Cuervo, H
  • Aragao, F
  • Munoz, J
  • Galindo, P
  • Merino, M
  • de la Fuente, B
  • Sepulveda, MA
  • Domingo, P
  • Garcia, J
  • Castano, M
  • Ribera, E
  • Geijo, P
  • Romero, A
  • Peraire, J
  • Deig, E
  • Roca, B
  • Martinez, E
  • Estrada, V
  • Berenguer, J
  • Espinosa, N

Grupos

Abstract

Background: Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. Objective: This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third agent among people living with HIV (PLWH). Methods: Data were from a multicenter Spanish PLWH cohort. Patients with a baseline estimated glomerular filtration rate (eGFR-EPI) measurement, >= 1 follow-up measurement, >= 30 days treatment with F/TAF, and who switched from F/TDF to F/TAF with no change in third agent were included. Multivariate mixed linear models were used to evaluate change from baseline over time in eGFR-EPI. eGFR-EPI changes before and after switch were analyzed in a matched patient subgroup. Results: Overall, 340 patients were included. Mean (95% CI) eGFR-EPI in patients with baseline eGFR-EPI <90 ml/min/1.73m(2) (n = 125) was 79.6 (78.0; 81.2) ml/min/1.73m(2) at baseline and 81.3 (79.9; 82.7) ml/min/1.73m(2) at 12 months after switch. In the patient-matched subgroup (n = 175), median annual eGFR-EPI declined -4.24 ml/min/1.73m(2) while on F/TDF and increased +0.93 ml/min/1.73m(2) after switch to F/TAF (P < 0.0001). In patients with baseline eGFR-EPI <90 ml/min/1.73m(2), median annual eGFR-EPI increased +4.19 mL/min/1.73m(2) after switch (P < 0.0001). Conclusion: Switching from F/TDF to F/TAF-based TT regimens while maintaining the same third agent numerically improved eGFR-EPI in PLWH with baseline eGFR-EPI <90 mL/min/1.73m(2). eGFR-EPI improved significantly when comparing progression while on F/TDF vs progression after switch, confirming beneficial renal effects of switching to F/TAF in a clinical practice setting.

Datos de la publicación

ISSN/ISSNe:
2578-7489, 2578-7470

HIV Research & Clinical Practice  TAYLOR & FRANCIS LTD

Tipo:
Article
Páginas:
78-85
PubMed:
34410219
Factor de Impacto:
0,612 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 3

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • HIV; estimated glomerular filtration rate; emtricitabine; tenofovir disoproxil fumarate; tenofovir alafenamide; switch; retrospective

Campos de Estudio

Cita

Compartir